Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy.
Medical Direction, Verona University Hospital Trust, Verona, Italy.
Eur J Cancer. 2020 Aug;135:159-169. doi: 10.1016/j.ejca.2020.05.029. Epub 2020 Jun 11.
On February 23rd, the 1st case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was diagnosed at the University Hospital Trust of Verona, Italy. On March 13th, the Oncology Section was converted into a 22-inpatient bed coronavirus disease (COVID) Unit, and we reshaped our organisation to face the SARS-CoV-2 epidemic, while maintaining oncological activities.
We tracked down (i) volumes of oncological activities (January 1st - March 31st, 2020 versus the same period of 2019), (ii) patients' and caregivers' perception and (iii) SARS-CoV-2 infection rate in oncology health professionals and SARS-CoV-2 infection-related hospital admissions of "active"' oncological patients.
As compared with the same trimester in 2019, the overall reduction in total numbers of inpatient admissions, chemotherapy administrations and specialist visits in January-March 2020 was 8%, 6% and 3%, respectively; based on the weekly average of daily accesses, reduction in some of the oncological activities became statistically significant from week 11. The overall acceptance of adopted measures, as measured by targeted questionnaires administered to a sample of 241 outpatients, was high (>70%). Overall, 8 of 85 oncology health professionals tested positive for SARS-CoV-2 infection (all but one employed in the COVID Unit, no hospital admissions and no treatment required); among 471 patients admitted for SARS-CoV-2 infection, 7 had an "active"' oncological disease (2 died of infection-related complications).
A slight, but statistically significant reduction in oncology activity was registered during the SARS-CoV-2 epidemic peak in Verona, Italy. Organisational and protective measures adopted appear to have contributed to keep infections in both oncological patients and health professionals to a minimum.
2020 年 2 月 23 日,意大利维罗纳大学医院信托基金会诊断出首例严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染病例。2020 年 3 月 13 日,肿瘤科被改造成一个拥有 22 张住院病床的冠状病毒病(COVID)病房,我们重组了组织架构以应对 SARS-CoV-2 疫情,同时保持肿瘤学活动。
我们追踪了(i)肿瘤学活动量(2020 年 1 月 1 日至 3 月 31 日与 2019 年同期相比),(ii)患者和护理人员的认知,以及(iii)肿瘤科卫生专业人员中的 SARS-CoV-2 感染率和“活动”期肿瘤患者的 SARS-CoV-2 感染相关住院率。
与 2019 年同期相比,2020 年 1 月至 3 月总住院人数、化疗次数和专科就诊人数分别减少了 8%、6%和 3%;基于每周平均每日就诊量,一些肿瘤学活动从第 11 周开始出现统计学显著减少。通过对 241 名门诊患者进行的目标问卷调查,我们发现对所采取措施的总体接受度较高(>70%)。共有 8 名(85 名)肿瘤科卫生专业人员的 SARS-CoV-2 检测呈阳性(除 1 人在 COVID 病房工作外,无人住院,无需治疗);在因 SARS-CoV-2 感染住院的 471 名患者中,有 7 名患有“活动”期肿瘤疾病(2 人死于感染相关并发症)。
在意大利维罗纳 SARS-CoV-2 疫情高峰期,肿瘤学活动量略有但具有统计学意义的减少。所采取的组织和保护措施似乎有助于将肿瘤患者和卫生专业人员的感染率保持在最低水平。